日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1

鲁马西兰治疗原发性高草酸尿症1型患者的长期疗效和安全性随机临床试验

Hulton, Sally A; Groothoff, Jaap W; Frishberg, Yaacov; Koren, Michael J; Overcash, J Scott; Sellier-Leclerc, Anne-Laure; Shasha-Lavsky, Hadas; Saland, Jeffrey M; Hayes, Wesley; Magen, Daniella; Moochhala, Shabbir H; Coenen, Martin; Simkova, Eva; Garrelfs, Sander F; Sas, David J; Meliambro, Kristin A; Ngo, Taylor; Sweetser, Marianne T; Habtemariam, Bahru A; Gansner, John M; McGregor, Tracy L; Lieske, John C

Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial

Lumasiran治疗原发性高草酸尿症1型的I/II期研究:一项安慰剂对照随机临床试验

Frishberg, Yaacov; Deschênes, Georges; Groothoff, Jaap W; Hulton, Sally-Anne; Magen, Daniella; Harambat, Jérôme; Van't Hoff, William G; Lorch, Ulrike; Milliner, Dawn S; Lieske, John C; Haslett, Patrick; Garg, Pushkal P; Vaishnaw, Akshay K; Talamudupula, Sandeep; Lu, Jiandong; Habtemariam, Bahru A; Erbe, David V; McGregor, Tracy L; Cochat, Pierre

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

FDA批准摘要:托珠单抗用于治疗嵌合抗原受体T细胞诱导的严重或危及生命的细胞因子释放综合征

Le, Robert Q; Li, Liang; Yuan, Weishi; Shord, Stacy S; Nie, Lei; Habtemariam, Bahru A; Przepiorka, Donna; Farrell, Ann T; Pazdur, Richard